SGO 2021 Annual Conference Virtual

We are extremely proud of our faculty, fellows and residents who are virtually presenting this week at the #SGOMtg Virtual Meeting. We’ll miss seeing everyone, but we are looking forward to next year!

MEETING website SGO schedule

Presentations featuring WashU

Friday, March 19, 2021

2:35-3:45 pm: Scientific Plenary I: Innovation and Progress in Gynecologic Oncology 
Fuh et al. Phase I study of GAS6/AXL inhibitor (AVB-500) in recurrent platinum-resistant ovarian cancer. 

1:00 pm – 2:15 pm: Speed Mentoring
Mentor: Khabele

5:30 pm – 6:45 pm: Breakout session: Oral Featured Poster Session: Omics, Equity, and Therapeutics-Oh My! 
Moderator: Khabele

5:30 pm – 6:45 pm: Fellow Applicant Networking Reception
Host: McCourt


Saturday, March 20, 2021

6:30 pm – 7:15 pm: Focused Plenary II: Translational Research 2021: A Window into Therapeutic Innovation 
Distillant: Fuh


Sunday, March 21, 2021

8:30 am – 9:45 am: Scientific Plenary IV: Endometrial Cancer: Moving to the Next Frontier 
Moderator: Thaker
Panelist: Powell

10:00 am -10:45 am: Focused Plenary VI: Preclinical Innovation – Exploring New Horizons
Moderator: Khabele

Mary M Mullen et al. Inducing carboplatin sensitivity with GAS6/AXL inhibition through increased replication stress. 

5:00 pm – 5:45 pm: Breakout session: Featured Poster Oral Presentations: Winter Meeting Edition 
Moderator: Hagemann

Stock et al. Increasing sensitivity to olaparib through inhibition of discoidin domain receptor 2 (DDR2) in homologous-recombination proficient ovarian cancer models 
Accepted- Oral


Monday, March 22, 2021

6:30 pm – 8:00 pm: Opportunistic Salpingectomy  
Moderator: Thaker

Poster Presentations

Friday 3/19 – Thursday 3/25/2021, 8:00 am – 11:00 pm

J.I. Tankou, M.D. Toboni, H. Noia, A. Oplt, D. Wilke, D. Khabele, L.M. Kuroki, A.R. Hagemann, C.K. McCourt, P.H. Thaker, D.G. Mutch, M.A. Powell and K.C. Fuh.  Inhibition of GAS6/AXL improves efficacy of HER2 inhibitor trastuzumab in uterine serous cancer. 

J.I. Tankou, Lisa Pollack, Elise Wilson, Iris Ko, Shaina Eckhouse, Su-Hsin Chang, Andrea Hagemann. Cost-effectiveness analysis comparing laparoscopic hysterectomy to combined laparoscopic hysterectomy and bariatric surgery in obese women with obesity-related disease and atypical endometrial hyperplasia or early-stage endometrial cancer. 

Abigail S. Zamorano, MD MPHS, Elise Wilson, MD, Esther Lu, PhD, Lindsay M. Kuroki, MD MSCI, Premal H. Thaker, MD MS, Carolyn K. McCourt, MD, Katherine C. Fuh, MD PhD, Matthew Powell, MD, David Mutch, MD, Dineo Khabele, MD, Graham Colditz, DrPH MD MPH, Andrea R. Hagemann, MD MSCI. Low Quality of Life and Activity Levels Persist in Obese Endometrial Cancer Survivors Despite Participation in a Behavioral Weight Loss Intervention. 

Elise Wilson, MD, Abigail S. Zamorano, MD, MPHS, Jingxia Liu, PhD, David Morris, PhD, Andrea Leon, BS, Lindsay M. Kuroki, MD, Premal H. Thaker, MD, MS, Carolyn K. McCourt, MD, Katherine C. Fuh, MD, PhD, L. Stewart Massad, MD, Matthew Powell, MD, David Mutch, MD, Dineo Khabele, MD, Graham Colditz, DrPH, MD, MPH, Andrea R. Hagemann, MD, MSCI.  Obese Endometrial Cancer Survivors’ Perceptions of Weight Loss Strategies and Characteristics that May Influence Participation in Behavioral Interventions.  

Johns EA, Stanley J, Toboni M, Schwarz J, Zhang F, Massad LS, Hagemann A, Fuh K, Thaker P, McCourt C, Grigsby P, Mutch D, Powell M, Khabele D, Kuroki L. Radiation therapy for vaginal and perirectal lesions in recurrent ovarian cancer. 

Lindsay M. Kuroki, MD, MSCI, David H. Morris, PhD, Molly Greenwade, MD, Megan Landon, BA, Andrea R. Hagemann, MD, MSCI, Premal H. Thaker, MD, MS, L. Stewart Massad, MD, Carolyn K McCourt, MD, Katherine C. Fuh, MD, PhD, Matthew Powell MD, David Mutch, MD, Dineo Khabele, MD, and Jessica R. Vanderlan, PhD.  Gynecologic oncology patients who are unemployed and underinsured face high distress that extends beyond financial toxicity. 

S.F. Bruce, H. Noia, E. Lomonosova, A. Oplt, E. Stock, D. Khabele, L.M. Kuroki, A.R. Hagemann, C.K. McCourt, P.H. Thaker, D.G. Mutch, M.A. Powell, K.C. Fuh.  AVB-500, a selective inhibitor of GAS6-AXL, shows improved therapeutic efficacy in combination with Paclitaxel in uterine serous carcinoma. 

S.F. Bruce, K. Cho, E. Lomonosova, H. Noia, E. Stock, D. Khabele, L.M. Kuroki, A.R. Hagemann, C.K. McCourt, P.H. Thaker, D.G. Mutch, M.A. Powell, G. Patti, K.C. Fuh. AVB-500, a selective inhibitor of GAS6-AXL, in combination with paclitaxel alters uterine serous cancer cell metabolism. 

E.S. Stock, A. Schab, S. Bruce, A. Oplt, E. Lomonosova, H. Noia, D. Khabele, L.M. Kuroki, A.R. Hagemann, C.K. McCourt, P.H. Thaker, D.G. Mutch, M.A. Powell and K.C. Fuh. Increasing sensitivity to olaparib through inhibition of Discoidin Domain Receptor 2 (DDR2) in homologous-recombination proficient ovarian cancer models. 

E.S. Stock, K Cho, E. Lomonosova, A. Schab, H. Noia, S. Bruce, D. Khabele, L.M. Kuroki, A.R. Hagemann, C.K. McCourt, P.H. Thaker, D.G. Mutch, M.A. Powell, G. Patti, and K.C. Fuh. Preventing cancer cell metastasis through inhibition of Discoidin Domain Receptor 2 (DDR2) in the tumor microenvironment: a metabolomic analysis. 

E.S. Stock, L Elson, H Noia, A Oplt, S Bruce, D Khabele, LM Kuroki, AR Hagemann, CK McCourt, PH Thaker, DG Mutch, MA Powell, KC Fuh.  Discoidin Domain Receptor 2 (DDR2) expression in combination with mutation status is predictive of survival in patients with ovarian cancer.  

Elizabeth Buckley, Mary M Mullen, Rehan Nizamuddin, Jonathan Stein, Lindsay M Kuroki, Katheine Fuh, Andrea Hagemann, Carolyn Mc Court, L. Stewart Massad, David G Mutch, Dineo Khabele, Matthew A. Powell, Joseph E. Ippolito, Premal H. Thaker. High Visceral fat to subcutaneous fat adiposity ratios portents a poor prognosis in patients with endometrial cancer.    

Katherine Fuh, Elena Lomonosova, Andrea Hagemann, Carolyn McCourt, Matthew Powell, Wendy Fantl, Premal Thaker.  Multi-dimensional biomarker analyses identify pembrolizumab responders in advance stage, high grade endometrial cancer. 

Whitney Grither, MD, PhD,  Breanna B. Baker, BS, Andrea R. Hagemann, MD, Dineo Khabele, MD, Lindsay Kuroki, MD, David Mutch, MD, Matthew A. Powell, MD, Premal H. Thaker, MD, Gregory D. Longmore, MD, Katherine C. Fuh, MD, PhD. Silencing ROR2 inhibits metastatic behavior of ovarian cancer cells.  

Whitney Grither, MD, PhD,  Vasilios A. Morikis, PhD, Breanna B. Baker, BS, Andrea R. Hagemann, MD, Dineo Khabele, MD, Lindsay Kuroki, MD, MSCI, David Mutch, MD, Matthew A. Powell, MD, Premal H. Thaker, MD, Katherine C. Fuh, MD, PhD, Gregory D. Longmore, MD. Wnt5a influences the directional displacement of ovarian cancer cells.   

Whitney Grither, MD, PhD, Molly Greenwade, MD, Marina Platik, PhD, Katherine C. Fuh, MD, PhD, Stephanie Markovina, MD, PhD, Premal H. Thaker, MD. Co-expression of PD-L1 and DDR2 in cervical cancer. 

Valentine MC, Perhandis JA, Hawkes  C, Thaker PH. Factors Affecting PARP inhibitor use as maintenance treatment in platinum sensitive recurrent ovarian cancer. 

Mary M. Mullen, MD, Zuhra Kortukovic, BS, Katherine C. Fuh, MD, PhD, Carolyn K. McCourt, MD, Andrea R. Hagemann, MD, MSCI, Premal H. Thaker, MD, MS, David G. Mutch, MD , Matthew A. Powell, MD, Dineo Khabele, MD, L. Stewart Massad, MD, Lindsay M. Kuroki, MD, MSCI.  Does antibiotic prophylaxis reduce wound complications after vulvar excision of premalignant lesions: A Pilot Double-Blinded Randomized Controlled Trial. 

M.D. Toboni, B. Blachut, E. Lomonosova, L.M. Kuroki, A.R. Hagemann, C.K. McCourt, P.H. Thaker, D.G. Mutch, D. Khabele , M.A. Powell, K.C. Fuh. Inducing homologous recombination deficiency using AVB500, a receptor tyrosine kinase AXL inhibitor in uterine serous cancer (USC). 

M.D. Toboni, Mary Mullen, Jo’an Tankou, Hollie Noia, Alyssa Oplt, Lindsay Kuroki, Andrea Hagemann, Carolyn McCourt, Premal Thaker, David Mutch, Dineo Khabele, Matthew Powell, Katherine Fuh.  AVB-500, a receptor tyrosine kinase AXL inhibitor, in combination with olaparib improves response in uterine serous cancer.

Thaker P, Holloway, Kuroki L, Bell M, DePasquale S, ElNaggar A, Bradley W, Indermaur M, Rocconi R, Gunderson C, Pothuri B, Bottsford-Miller J, Agajanian R, Bregar Am, Warhal D, Provencher D, McHale M, John V, Bergman M, Lau S, Musso L, Anwer K, Borys N, Leath C. A Phase I/II study Evaluating Intraperitoneal GEN-1 in Combination with Neoadjuvant Chemotherapy in Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer 
Trials in Progress Poster 

Ramy Gadalla, Ben X. Wang, David G. Brooks, Daniela Matei, Panagiotis Konstantinopoulos, Matthew Block, Andrea Jewell, Stephanie Gaillard, Michael McHale, Carolyn McCourt, Sarah Temkin, Eugenia Girda, Floor Backes, Theresa L Werner, Linda Duska, Siobhan Kehoe, Ilaria Colombo, Rachel Wildman, John Wright, Gini Fleming, Pamela S. Ohashi, Stephanie Lheureux.  Immune profiling of advanced, recurrent metastatic endometrial cancer using high-dimensional time-of-flight mass cytometry (CyTOF). Submitted